ATC
IBB icon

Advantage Trust Company’s iShares Biotechnology ETF IBB Stock Holding History

Advantage Trust Company’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$916K Buy
4,817
+140
+3% +$24.1K 0.32% 25
2026
Q1 		$790K Hold
4,677
– – 0.35% 21
2025
Q4 		$789K Hold
4,677
– – 0.36% 20
2025
Q3 		$675K Sell
4,677
-375
-7% -$51.2K 0.31% 26
2025
Q2 		$639K Sell
5,052
-86
-2% -$10.6K 0.31% 27
2025
Q1 		$657K Sell
5,138
-4,220
-45% -$572K 0.4% 23
2024
Q4 		$1.24M Sell
9,358
-4,344
-32% -$611K 0.73% 15
2024
Q3 		$2M Buy
13,702
+63
+0.5% +$9.12K 1.35% 15
2024
Q2 		$1.87M Sell
13,639
-270
-2% -$36K 1.34% 14
2024
Q1 		$1.91M Sell
13,909
-358
-3% -$48.9K 1.41% 15
2023
Q4 		$1.94M Buy
+14,267
New +$1.74M 1.53% 16

Other funds holding IBB

WA
WestEnd Advisors Charlotte, North Carolina $4.49B AUM 19.44% 1-Year Est. Return
AFG
Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
AP
Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return
CA
Cumberland Advisors Sarasota, Florida $284M AUM 27.11% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return

Advantage Trust Company's IBB Position: Q2 2026 in Review

Advantage Trust Company increased its iShares Biotechnology ETF (IBB) stake by 3% in Q2 2026, buying an estimated $24.1K and bringing the position to 4,817 shares worth $916K. The position accounts for 0.32% of the portfolio, ranked #25.

Advantage Trust Company first reported a position in IBB in Q4 2023 and has held it in 11 quarters since. The position peaked at $2M in Q3 2024. 285 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Advantage Trust Company held 4,817 shares of iShares Biotechnology ETF worth $916K as of Q2 2026.
  • Advantage Trust Company bought 140 iShares Biotechnology ETF shares in Q2 2026, an estimated $24.1K.
  • iShares Biotechnology ETF made up 0.32% of Advantage Trust Company's portfolio in Q2 2026, its #25 holding.
  • Advantage Trust Company first reported a position in iShares Biotechnology ETF in Q4 2023 and has held it in 11 quarters since.
  • Advantage Trust Company's iShares Biotechnology ETF position peaked at $2M in Q3 2024.
  • 285 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Advantage Trust Company's 13F filing for Q2 2026, filed 17 Jul 2026.